AU2017341753B2 - Formulations for enteric delivery of therapeutic agents - Google Patents

Formulations for enteric delivery of therapeutic agents Download PDF

Info

Publication number
AU2017341753B2
AU2017341753B2 AU2017341753A AU2017341753A AU2017341753B2 AU 2017341753 B2 AU2017341753 B2 AU 2017341753B2 AU 2017341753 A AU2017341753 A AU 2017341753A AU 2017341753 A AU2017341753 A AU 2017341753A AU 2017341753 B2 AU2017341753 B2 AU 2017341753B2
Authority
AU
Australia
Prior art keywords
therapeutic agent
nanoparticles
formulation
polymer
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017341753A
Other languages
English (en)
Other versions
AU2017341753A1 (en
Inventor
Indu Javeri
Kaliappanadar Nellaiappan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curirx Inc
Original Assignee
Curirx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curirx Inc filed Critical Curirx Inc
Publication of AU2017341753A1 publication Critical patent/AU2017341753A1/en
Application granted granted Critical
Publication of AU2017341753B2 publication Critical patent/AU2017341753B2/en
Priority to AU2024201438A priority Critical patent/AU2024201438A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C07K16/11—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
AU2017341753A 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents Active AU2017341753B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201438A AU2024201438A1 (en) 2016-10-12 2024-03-05 Formulations for enteric delivery of therapeutic agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/291,480 US11491114B2 (en) 2016-10-12 2016-10-12 Formulations for enteric delivery of therapeutic agents
US15/291,480 2016-10-12
PCT/US2017/056320 WO2018071655A1 (en) 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201438A Division AU2024201438A1 (en) 2016-10-12 2024-03-05 Formulations for enteric delivery of therapeutic agents

Publications (2)

Publication Number Publication Date
AU2017341753A1 AU2017341753A1 (en) 2019-05-30
AU2017341753B2 true AU2017341753B2 (en) 2023-12-07

Family

ID=61830540

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017341753A Active AU2017341753B2 (en) 2016-10-12 2017-10-12 Formulations for enteric delivery of therapeutic agents
AU2024201438A Abandoned AU2024201438A1 (en) 2016-10-12 2024-03-05 Formulations for enteric delivery of therapeutic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201438A Abandoned AU2024201438A1 (en) 2016-10-12 2024-03-05 Formulations for enteric delivery of therapeutic agents

Country Status (8)

Country Link
US (2) US11491114B2 (cg-RX-API-DMAC7.html)
EP (1) EP3525772A4 (cg-RX-API-DMAC7.html)
JP (1) JP7046081B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230135694A (cg-RX-API-DMAC7.html)
CN (1) CN110049759A (cg-RX-API-DMAC7.html)
AU (2) AU2017341753B2 (cg-RX-API-DMAC7.html)
CA (1) CA3078570A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018071655A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019097251A1 (en) * 2017-11-17 2019-05-23 Intract Pharma Limited Novel compositions
CN113660953A (zh) * 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
CN111743880B (zh) * 2020-06-05 2022-03-08 浙江大学医学院附属第一医院 一种单抗类药物口服纳米-微球制剂及其制备方法
WO2022006051A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Formulation of tocilizumab and method for treating covid-19 by inhalation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098205A1 (en) * 2005-09-15 2009-04-16 Council Of Scientife & Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
ATE158180T1 (de) 1991-06-21 1997-10-15 Univ Cincinnati Oral verabreichbare therapeutische proteine und herstellungsverfahren
DE69411154T2 (de) 1993-02-22 1998-10-22 Alza Corp., Palo Alto, Calif. Mittel zur oralen gabe von wirkstoffen
JPH10503179A (ja) 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
FR2775435B1 (fr) 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
FR2786098B1 (fr) * 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
DK1429731T3 (da) 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20050181059A1 (en) * 2003-09-30 2005-08-18 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
NZ546379A (en) 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US20040224019A1 (en) 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7541028B2 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
US20080241260A1 (en) * 2005-09-28 2008-10-02 Padma Venkitachalam Devarajan Compositions for Enhanced Absorption of Biologically Active Agents
WO2008031770A2 (en) 2006-09-12 2008-03-20 Cosmo Technologies Ltd Pharmaceutical compositions for the oral or rectal administration of protein substances
JP2010505877A (ja) 2006-10-05 2010-02-25 ザ・ジョンズ・ホプキンス・ユニバーシティー スマートな高分子ナノ粒子を用いた低水溶性薬物用の水分散性経口、非経口および局所的製剤
WO2008065502A1 (en) 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2009010842A2 (en) 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009135854A2 (en) 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation of biologically active agents
US20110189299A1 (en) * 2008-07-01 2011-08-04 Nitto Denko Corporation Pharmaceutical composition containing surface-coated microparticles
US20100021549A1 (en) 2008-07-28 2010-01-28 Flamel Technologies, S.A. Microparticle oral form useful for the modified release of nanoparticles
FR2934161B1 (fr) 2008-07-28 2010-09-17 Flamel Tech Sa Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules.
GB0815852D0 (en) 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
WO2010113177A2 (en) 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
US8673359B2 (en) 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
CN102614498B (zh) * 2011-01-28 2014-12-17 四川科伦药物研究有限公司 一种胰岛素纳米粒及其制备方法
WO2012170547A1 (en) 2011-06-06 2012-12-13 Perosphere, Inc. Bioadhesive drug delivery compositions
EP2548571A1 (en) * 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
CN102908332B (zh) * 2011-08-04 2014-04-16 纳米及先进材料研发院有限公司 用于口服胰岛素递送的包含阳离子纳米粒子的肠溶包衣胶囊
US8859004B2 (en) 2011-08-04 2014-10-14 Nano And Advanced Materials Institute Limited pH-sensitive nanoparticles for oral insulin delivery
AU2012325723A1 (en) 2011-10-21 2014-05-15 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules
AU2013208324B2 (en) 2012-01-13 2017-11-23 Xspray Microparticles Ab A pharmaceutical composition comprising stable, amorphous hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component
WO2013160773A2 (en) 2012-04-23 2013-10-31 Nanogen Pharmaceuticals Polymeric nanoparticles and a process of preparation thereof
US9622982B2 (en) * 2013-01-14 2017-04-18 Health Clinics Limited Cancer drug and uses
US9833522B2 (en) * 2013-12-23 2017-12-05 The Research Foundation For The State University Of New York Graphene-based contrast agents for photoacoustic and thermoacoustic tomography and method of use
AU2015265872B2 (en) 2014-05-30 2020-04-09 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
US9370488B2 (en) 2014-07-21 2016-06-21 Kimia Zist Parsian Method and system for synthesizing nanocarrier based long acting drug delivery system for insulin
PT107846B (pt) 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
US9937256B2 (en) 2015-01-14 2018-04-10 Board Of Regents, The University Of Texas System Hydrogels for delivery of therapeutic compounds
CN104739806B (zh) * 2015-04-17 2018-04-03 黑龙江大学 口服胰岛素复合微囊及制备方法
CN105056212B (zh) * 2015-07-14 2018-06-15 江西省药物研究所 一种提高胰岛素口服结肠吸收的壳聚糖纳米粒及制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098205A1 (en) * 2005-09-15 2009-04-16 Council Of Scientife & Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES

Also Published As

Publication number Publication date
CN110049759A (zh) 2019-07-23
EP3525772A1 (en) 2019-08-21
KR20190086446A (ko) 2019-07-22
KR102580705B1 (ko) 2023-09-19
EP3525772A4 (en) 2020-06-03
CA3078570A1 (en) 2018-04-19
US20230034964A1 (en) 2023-02-02
US11491114B2 (en) 2022-11-08
WO2018071655A1 (en) 2018-04-19
US20180098946A1 (en) 2018-04-12
KR20230135694A (ko) 2023-09-25
AU2017341753A1 (en) 2019-05-30
AU2024201438A1 (en) 2024-03-21
BR112019007539A2 (pt) 2019-07-02
JP2019534897A (ja) 2019-12-05
JP7046081B2 (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
US20230034964A1 (en) Formulations for Enteric Delivery of Therapeutic Agents
ES2700278T3 (es) Formulaciones para efectores de la unión estrecha
US9149441B2 (en) Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US20020054914A1 (en) Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
JP6533232B2 (ja) 親水性活性化合物のナノカプセル化
KR20080002689A (ko) 세팔로스포린을 함유하는 나노미립자 및 조절 방출 조성물
CN102387789A (zh) 含有无定形cddo-me的延迟释放口服组合物
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
AU2018287142B2 (en) Albumin nanoparticles for the treatment of cancer and ocular diseases
Elsebay et al. Nanosuspension: a formulation technology for tackling the poor aqueous solubility and bioavailability of poorly soluble drugs
Zamanian et al. Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms
CN101773466B (zh) 一种口服纳米聚合物胶束载药系统及其制备方法
BR112019007539B1 (pt) Formulação oral de um agente terapêutico, método de preparação de uma formulação administrável por via oral de um agente terapêutico e uso da referida formulação oral
CN106924184B (zh) 一种眼部玻璃体注射用多囊脂质体及其制备方法
Mohammed Development of Once-Daily Mycophenolate Mofetil Sustained Release Oral Nanoparticles
Lu et al. Appendix F—Chapter II. 5.16—Drug Delivery Systems: H, Mucosal Drug Delivery
CN119909163A (zh) 一种基于糖链修饰与相变材料的长效稳定重组rsv疫苗

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)